Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...
Elevated blood pressure is the most important risk factor for cardiovascular disease. Numerous clinical practice guidelines ...
George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia ...
Patients aged 65 years and older who use acetaminophen demonstrate greater risks for serious complications, including ...
Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...
The consequences of primary aldosteronism mainly result from the activation of the mineralocorticoid receptor. Two of these ...
The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...
On Monday, the Centers for Medicare & Medicaid Services (CMS) initiated a national coverage analysis of renal denervation for the treatment of uncontrolled hypertension.
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...
Hypertension is an easily diagnosed and (potentially ... Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003 May 21; 289:2560-72. Psaty BM et al.
High blood pressure silently affects millions worldwide, often showing no symptoms until significant damage has occurred.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback